Straits Times Index
3,291.71 -0.98 (-0.03%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,190.27 +427.24 (+2.41%) FTSE 100
8,121.24 -22.89 (-0.28%) Bitcoin USD
57,548.07 -2,325.97 (-3.88%) CMC Crypto 200
1,259.57 -11.18 (-0.88%)
NVO Jan 2026 87.500 put
| Previous close | 4.1500 |
| Open | 4.1500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 87.50 |
| Expiry date | 2026-01-16 |
| Day's range | 4.1500 - 4.1500 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- Yahoo Finance Video
Apple, Novo Nordisk earnings, jobless claims: What to watch
A number of companies release their quarterly earning reports on Thursday, including Apple (AAPL), Novo Nordisk (NVO), Shell (SHEL), ConocoPhillips (COP), Cigna (CI), Coinbase (COIN), Moderna (MRNA), DraftKings (DKNG), Kellanova (K), United States Steel (X), and more. On the economic front, jobless claims for the week ending on April 27 will be released. Economists expect claims to rise to 212,000 from 207,000 the prior week. For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. This post was written by Nicholas Jacobino
- Reuters
UPDATE 2-Novo Nordisk raises outlook fuelled by obesity drug demand
Novo Nordisk raised its 2024 outlook on Thursday and delivered better-than-expected quarterly profits as the Danish drugmaker races to boost output of its hugely popular weight-loss drug Wegovy and fend off competition from rival Eli Lilly. The small raise to the outlook and forecast-beating results underscore Wegovy's success and Novo's lead in the fast-growing obesity drug market, which analysts have estimated could be worth as much as $100 billion by the end of the decade. Novo's growth on the back of the phenomenal success of Wegovy has nonetheless been held back by its ability to meet runaway demand for the weekly injection.
ReutersNovo Nordisk raises outlook fuelled by obesity drug demand
Novo Nordisk raised its 2024 outlook on Thursday and delivered better-than-expected quarterly profits as the Danish drugmaker races to boost output of its hugely popular weight-loss drug Wegovy and fend off competition from rival Eli Lilly. The small raise to the outlook and forecast-beating results underscore Wegovy's success and Novo's lead in the fast-growing obesity drug market, which analysts have estimated could be worth as much as $100 billion by the end of the decade. Novo's growth on the back of the phenomenal success of Wegovy has nonetheless been held back by its ability to meet runaway demand for the weekly injection.
